Venous thromboembolism prevention

Eikelboom JW, Quinlan DJ, O Doimell M. Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. Circulation 2009 120(20) 2006-11. 

Prevention of Venous Thromboembolism in the Intensive Care Unit Patient... 

Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 126 338SM 00S. 

Combined estrogen plus progestin should not be used in the prevention of chronic diseases because it increases the risk of CHD, stroke, breast cancer, and venous thromboembolism. 

CHD is the leading cause of death among women in the United States. Retrospective data indicated that HRT was associated with a decrease in risk of CHD by 30% to 50%.21 However, the results of recent RCTs demonstrate that HRT does not prevent or treat CHD in women and that it actually may cause an increase in CHD events. The HERS, published in 1998, was the first RCT conducted in women with established CHD. This trial demonstrated an increased incidence of CHD events within the first year of treatment with HRT and an increased risk of venous thromboembolism (VTE) and gallbladder disease. There was a trend of decreasing incidence... 

Decensi A, Maisonneuve P, Rotmenz N et al. (2005) Effect of Tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation 111 650-656... 

Evans HC, Perry CM, Eaulds D. Ximelagatran/ Melagatran.A review of its use in the prevention of venous thromboembolism in orthopaedic surgery. Drugs 2004 64 649-78. 

Miller J, Chan BKS, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism a systematic review and meta-analysis for the U.S. Preventive Services Task Eorce. Ann Intern Med 2002 136 680-90. 

---